Post by Acapedia

🔬 Cross-Continental Genomic Study Challenges Age Cut-Offs in AML 🧬 Study Overview A large-scale analysis of 2,823 adult AML patients from the USA and Germany reveals that: • Age-related genetic trends exist — but no clear “younger vs. older” boundary can be defined. • Mutational patterns and outcomes change continuously, not categorically. • Survival declines linearly with age, even within all ELN 2022 genetic-risk groups. 📊 Key Findings ✅ Molecular shifts with age: ↑ ASXL1, IDH1/2, RUNX1, SRSF2, TET2, TP53 mutations ↓ CEBPA, KIT, KRAS, WT1 mutations and core-binding factor rearrangements ✅ Survival impact: • 5-year OS ranges from 73% (ages 18–24) → 21% (≥75 years) in favorable-risk AML • No single age threshold predicts molecular change or outcome ✅ Clinical takeaway: “Age is a continuum in AML — treatment and trial design should focus on molecular biology and patient fitness, not arbitrary age limits.” 🌍 Why It Matters Rigid age-based eligibility may exclude patients from targeted therapies and distort real-world evidence. This study supports a precision oncology approach integrating genomic risk + functional status over chronologic age. 👩‍🔬 Authors: Monica Cusan, Karilyn Larkin, Deedra Nicolet, Vindi Jurinovic, Krzysztof Mrózek, Aarif Mohamed Nazeer Batcha, Maja Rothenberg-Thurley, Steven Schneider, Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Philipp A. Greif, James Blachly, Alice S. Mims, Christopher J. Walker, Michael C. Walker, Christopher C. Oakes, Shelley Orwick, Andrew J. Carroll, William G. Blum, Bayard L. Powell, Jonathan Kolitz, Joseph O. Moore, Robert J. Mayer, Richard A. Larson, Richard M. Stone, John Byrd, Klaus Metzeler, Tobias Herold, Ann-Kathrin Eisfeld https://lnkd.in/dYuqES3Y #AML #Leukemia #OncologyResearch #PrecisionMedicine #Genomics #ELN2022 #ClinicalTrials #AgeContinuum #Hematology #RealWorldData #CancerGenomics #AMLResearch